ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "bd783ef0-2a95-4e99-b231-1ee32e3599a4"}, "_deposit": {"id": "18678", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "18678"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00018678", "sets": ["456", "1139"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "Current Status and Prospects of Therapy for Malignant Ovarian Tumour"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1995-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "154", "bibliographicPageStart": "149", "bibliographicVolumeNumber": "109", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "From January 1983 through December 1991, 320 patients with epithelial ovarian cancer were treated at 4 institutions including our hospital. The patients were analyzed as to their condition and treatment method such as FIGO stage, tumor type, type of surgery, and diameter of residual tumor at second look operation (SLO). The breakdown of the patients regarding clinical stage was 33.8 % in stage I, 15.3 % in stage II, 40.0 % in stage III and 10.9 % in stage IV. The rate of complete removal in initial surgery was 99.1 % in stage I, 73.5 % in stage II, 12.5 % in stage III and 11.4 % in stage IV. Sixty six percent of patients in stage III and stage IV had unresectable tumors of more than 2 cm in diameter. SLO reveraled persistnt or recurrent tumor in 1.4 % of stage I, 16.7 % of stage II, 18.2 % of stage III and 66.7 9% of stage IV. Prognosis was also analyzed acording to prognostic clinical characteristics. The 5-year survival rate was 93.0 % in stage I, 70.4 % in stage II, 30.5 % in stage III and 9.5 % in stage IV. The overall survival rate was 54.2 %. The patients who had undergone SLO with complete removal at the initial operatin had better prognosis than those who had not. The 5-year survival rate of those with and without SLO was 97.1 % v.s. 91.2 % in stage I, 75.5 % v.s. 53.0 % in stage II, and 85.7 % v.s. 80.0 % in stage III. Recent combined treatment using of tumor-infiltrating lymphocytes (TIL) and cisplatin-containing chemotherapy showed better prognosis than chemotherapy alone ; survival rate was 83.7 % v.s. 27.3 % (p\u003c0.05). The result suggests that this combination therapy may be hopefull for advanced ovarian cancer.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "116737", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Kodama, Shoji"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "児玉, 省二"}], "nameIdentifiers": [{"nameIdentifier": "116736", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-08"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "109(4)_149-154.pdf", "filesize": [{"value": "939.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 939200.0, "url": {"label": "109(4)_149-154.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/18678/files/109(4)_149-154.pdf"}, "version_id": "fd9569c7-b636-4169-93ae-626a9d55e22e"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "ovarian cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prognostic factor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "tumor-infiltrating lymphocytes (TIL)", "subitem_subject_scheme": "Other"}, {"subitem_subject": "卵巣癌", "subitem_subject_scheme": "Other"}, {"subitem_subject": "予後因子", "subitem_subject_scheme": "Other"}, {"subitem_subject": "養子免疫療法", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "悪性卵巣腫瘍治療の現況と展望", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "悪性卵巣腫瘍治療の現況と展望"}, {"subitem_title": "悪性卵巣腫瘍治療の現況と展望", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1139"], "permalink_uri": "http://hdl.handle.net/10191/42311", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-06-27"}, "publish_date": "2016-06-27", "publish_status": "0", "recid": "18678", "relation": {}, "relation_version_is_last": true, "title": ["悪性卵巣腫瘍治療の現況と展望"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 03 紀要論文
  1. 250 大学院医歯学総合研究科(医)
  2. 20 紀要
  3. 02 新潟医学会雑誌
  4. 第109巻第4号

悪性卵巣腫瘍治療の現況と展望

http://hdl.handle.net/10191/42311
http://hdl.handle.net/10191/42311
22997976-9304-45b5-93c3-d4ad434ec13f
名前 / ファイル ライセンス アクション
109(4)_149-154.pdf 109(4)_149-154.pdf (939.2 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2016-06-27
タイトル
タイトル 悪性卵巣腫瘍治療の現況と展望
タイトル
言語 en
タイトル 悪性卵巣腫瘍治療の現況と展望
言語
言語 jpn
キーワード
主題Scheme Other
主題 ovarian cancer
キーワード
主題Scheme Other
主題 prognostic factor
キーワード
主題Scheme Other
主題 tumor-infiltrating lymphocytes (TIL)
キーワード
主題Scheme Other
主題 卵巣癌
キーワード
主題Scheme Other
主題 予後因子
キーワード
主題Scheme Other
主題 養子免疫療法
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
その他のタイトル
その他のタイトル Current Status and Prospects of Therapy for Malignant Ovarian Tumour
著者 児玉, 省二

× 児玉, 省二

WEKO 116736

児玉, 省二

Search repository
著者別名
識別子 116737
識別子Scheme WEKO
姓名 Kodama, Shoji
抄録
内容記述タイプ Abstract
内容記述 From January 1983 through December 1991, 320 patients with epithelial ovarian cancer were treated at 4 institutions including our hospital. The patients were analyzed as to their condition and treatment method such as FIGO stage, tumor type, type of surgery, and diameter of residual tumor at second look operation (SLO). The breakdown of the patients regarding clinical stage was 33.8 % in stage I, 15.3 % in stage II, 40.0 % in stage III and 10.9 % in stage IV. The rate of complete removal in initial surgery was 99.1 % in stage I, 73.5 % in stage II, 12.5 % in stage III and 11.4 % in stage IV. Sixty six percent of patients in stage III and stage IV had unresectable tumors of more than 2 cm in diameter. SLO reveraled persistnt or recurrent tumor in 1.4 % of stage I, 16.7 % of stage II, 18.2 % of stage III and 66.7 9% of stage IV. Prognosis was also analyzed acording to prognostic clinical characteristics. The 5-year survival rate was 93.0 % in stage I, 70.4 % in stage II, 30.5 % in stage III and 9.5 % in stage IV. The overall survival rate was 54.2 %. The patients who had undergone SLO with complete removal at the initial operatin had better prognosis than those who had not. The 5-year survival rate of those with and without SLO was 97.1 % v.s. 91.2 % in stage I, 75.5 % v.s. 53.0 % in stage II, and 85.7 % v.s. 80.0 % in stage III. Recent combined treatment using of tumor-infiltrating lymphocytes (TIL) and cisplatin-containing chemotherapy showed better prognosis than chemotherapy alone ; survival rate was 83.7 % v.s. 27.3 % (p<0.05). The result suggests that this combination therapy may be hopefull for advanced ovarian cancer.
書誌情報 新潟医学会雑誌
en : 新潟医学会雑誌

巻 109, 号 4, p. 149-154, 発行日 1995-04
出版者
出版者 新潟医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 00290440
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AN00182415
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:46:22.967789
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3